BACKGROUND: Chemotherapy has improved the outcome of patients with newly diagnosed osteosarcoma, but its role in relapsed disease is unclear. METHODS: We reviewed the records of all patients who were treated for relapsed high-grade osteosarcoma at our institution between 1970 and 2004. Postrelapse event-free survival (PREFS) and postrelapse survival (PRS) were estimated, and outcome comparisons were made using an exact log-rank test. RESULTS: The 10-year PREFS and PRS of the 110 patients were 11.8% ± 3.5% and 17.0% ± 4.3%, respectively. Metastasis at initial diagnosis (14%), and relapse in lung only (75%) were not significantly associated with PREFS or PRS. Time from initial diagnosis to first relapse (RL1) ≥18 months (43%), surgery at RL1 (76%), and ability to achieve second complete remission (CR2, 56%) were favorably associated with PREFS and PRS (P ≤ 0.0002). In patients without CR2, chemotherapy at RL1 was favorably associated with PREFS (P = 0.01) but not with PRS. In patients with lung relapse only, unilateral relapse and number of nodules ( ≤ 3) were associated with better PREFS and PRS (P ≤ 0.0005); no patients with bilateral relapse survived 10 years. The median PREFS after treatment with cisplatin, doxorubicin, methotrexate, and ifosfamide was 3.5 months (95% confidence interval, 2.1-5.2), and the median PRS was 8.2 months (95% confidence interval, 5.2-15.1). CONCLUSIONS: Late relapse, surgical resection, and unilateral involvement (in lung relapse only) favorably impact outcome after relapse. Surgery is essential for survival; chemotherapy may slow disease progression in patients without CR2. These data are useful for designing clinical trials that evaluate novel agents.
BACKGROUND: Chemotherapy has improved the outcome of patients with newly diagnosed osteosarcoma, but its role in relapsed disease is unclear. METHODS: We reviewed the records of all patients who were treated for relapsed high-grade osteosarcoma at our institution between 1970 and 2004. Postrelapse event-free survival (PREFS) and postrelapse survival (PRS) were estimated, and outcome comparisons were made using an exact log-rank test. RESULTS: The 10-year PREFS and PRS of the 110 patients were 11.8% ± 3.5% and 17.0% ± 4.3%, respectively. Metastasis at initial diagnosis (14%), and relapse in lung only (75%) were not significantly associated with PREFS or PRS. Time from initial diagnosis to first relapse (RL1) ≥18 months (43%), surgery at RL1 (76%), and ability to achieve second complete remission (CR2, 56%) were favorably associated with PREFS and PRS (P ≤ 0.0002). In patients without CR2, chemotherapy at RL1 was favorably associated with PREFS (P = 0.01) but not with PRS. In patients with lung relapse only, unilateral relapse and number of nodules ( ≤ 3) were associated with better PREFS and PRS (P ≤ 0.0005); no patients with bilateral relapse survived 10 years. The median PREFS after treatment with cisplatin, doxorubicin, methotrexate, and ifosfamide was 3.5 months (95% confidence interval, 2.1-5.2), and the median PRS was 8.2 months (95% confidence interval, 5.2-15.1). CONCLUSIONS: Late relapse, surgical resection, and unilateral involvement (in lung relapse only) favorably impact outcome after relapse. Surgery is essential for survival; chemotherapy may slow disease progression in patients without CR2. These data are useful for designing clinical trials that evaluate novel agents.
Authors: Alexander J Chou; Pamela R Merola; Leonard H Wexler; Richard G Gorlick; Yatin M Vyas; John H Healey; Michael P LaQuaglia; Andrew G Huvos; Paul A Meyers Journal: Cancer Date: 2005-11-15 Impact factor: 6.860
Authors: W H Meyer; C B Pratt; C A Poquette; B N Rao; D M Parham; N M Marina; A S Pappo; H H Mahmoud; J J Jenkins; J Harper; M Neel; B D Fletcher Journal: J Clin Oncol Date: 2001-01-01 Impact factor: 44.544
Authors: G Bacci; S Ferrari; A Longhi; S Perin; C Forni; N Fabbri; N Salduca; M Versari; K V Smith Journal: Eur J Cancer Date: 2001-01 Impact factor: 9.162
Authors: Judy Y Ou; Holly Spraker-Perlman; Andrew C Dietz; Rochelle R Smits-Seemann; Sapna Kaul; Anne C Kirchhoff Journal: Cancer Epidemiol Date: 2017-10-07 Impact factor: 2.984
Authors: Todd E Heaton; William J Hammond; Benjamin A Farber; Valerie Pallos; Paul A Meyers; Alexander J Chou; Anita P Price; Michael P LaQuaglia Journal: J Pediatr Surg Date: 2016-10-27 Impact factor: 2.545
Authors: Barrie Cohen; Michael Roth; Jonathan M Marron; Stacy W Gray; David S Geller; Bang Hoang; Richard Gorlick; Katherine A Janeway; Jonathan Gill Journal: Ann Surg Oncol Date: 2016-07-26 Impact factor: 5.344
Authors: Jonathan M Marron; Steven G DuBois; Julia Glade Bender; AeRang Kim; Brian D Crompton; Stephanie C Meyer; Katherine A Janeway; Jennifer W Mack Journal: Pediatr Blood Cancer Date: 2016-07-18 Impact factor: 3.167